Regentis Biomaterials (RGNT) Cash & Equivalents (2024 - 2025)
Regentis Biomaterials' (RGNT) quarterly Cash & Equivalents came in at $7.4 million in Q4 2025, up 3121.83% year-on-year from $229000.0 in Q4 2024, and up 3121.83% on a QoQ basis from $229000.0 in Q4 2024.
Regentis Biomaterials (RGNT) Cash & Equivalents (2024 - 2025) Analysis & Trends
Regentis Biomaterials (RGNT) has 2 years of Cash & Equivalents data on file, last reported at $7.4 million in Q4 2025.
- On a quarterly basis, Cash & Equivalents rose 3121.83% year-over-year to $7.4 million in Q4 2025; TTM through Dec 2025 was $7.4 million, a 3121.83% increase from a year earlier, with the FY2025 full-year figure at $7.4 million, up 3121.83% from the prior year.
- Cash & Equivalents for Q4 2025 stood at $7.4 million, up from $229000.0 in the prior quarter.
- Over the last five years, Cash & Equivalents for RGNT reached as high as $7.4 million in Q4 2025 and fell as low as $229000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alcon | 32,734,969.19 Bn | 32,734,967.53 Bn | 1.53 Bn | 1.58 Bn |
| 2 | Intuitive Surgical | 117.50 Bn | 112.41 Bn | 1.96 Bn | 2.76 Bn |
| 3 | Becton Dickinson | 42.93 Bn | 42.11 Bn | 2.15 Bn | 813.00 Mn |
| 4 | Medline | 30.82 Bn | 36.66 Bn | 1.84 Bn | 2.24 Bn |
| 5 | Resmed | 27.90 Bn | 26.23 Bn | 890.98 Mn | 1.66 Bn |
| 6 | West Pharmaceutical Services | 26.76 Bn | 26.23 Bn | 329.20 Mn | 435.80 Mn |
| 7 | Cooper Companies | 15.30 Bn | 15.16 Bn | 735.40 Mn | 138.80 Mn |
| 8 | Solventum | 13.46 Bn | 12.90 Bn | 1.10 Bn | 561.00 Mn |
| 9 | Align Technology | 12.02 Bn | 10.96 Bn | 736.59 Mn | 1.06 Bn |
| 10 | Regentis Biomaterials | 1.10 Mn | -6.28 Mn | - | 7.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.38 Mn |
| Dec 31, 2024 | 229,000.00 |